Career Pivot: A Physician's Guide to What's Next
1.0 CME Credits
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
2 hours ago
- Health Line
Anxiety Diagnosis
Key takeaways Diagnosing anxiety requires a comprehensive approach, including a physical examination and a thorough review of your personal history to rule out other medical conditions that may mimic anxiety symptoms. Various self-assessment questionnaires and clinical assessments, such as the Zung Self-Rating Anxiety Scale and the Hamilton Anxiety Scale, are used to evaluate the level and severity of anxiety. Effective management of anxiety involves a combination of medication, therapy, lifestyle adjustments, and open communication with family and friends. Read on to learn more about the process of diagnosing anxiety. During the physical examination You should be completely honest with your doctor. Many things can contribute to or be affected by anxiety, including: certain illnesses medications alcohol consumption coffee consumption hormones Other medical conditions can cause symptoms that resemble anxiety. Many anxiety symptoms are physical, including: racing heart shortness of breath shaking sweating chills hot flashes chest pain twitching dry mouth nausea vomiting diarrhea frequent urination Your doctor may perform a physical exam and order a variety of tests to rule out medical conditions that mimic anxiety symptoms. Medical conditions with similar symptoms include: heart attack angina mitral valve prolapse tachycardia asthma hyperthyroidism adrenal gland tumors menopause side effects of certain drugs, such as drugs for high blood pressure, diabetes, and thyroid disorders withdrawal from certain drugs, such as those used to treat anxiety and sleep disorders substance abuse or withdrawal Diagnostic tests It's suggested that you complete a self-assessment questionnaire before other testing. This can help you decide whether you may have an anxiety disorder or if you may be reacting to a certain situation or event. If your self-assessments lead you to believe that you may have an anxiety disorder, your doctor may then ask you to take a clinical assessment or conduct a structured interview with you. Your doctor may use one or more of the following tests to assess your level of anxiety. Zung Self-Rating Anxiety Scale The Zung test is a 20-item questionnaire. It asks you to rate your anxiety from 'a little of the time' to 'most of the time' on subjects such as: nervousness anxiety shaking rapid heartbeat fainting frequent urination nightmares Once you complete this test, a trained professional assesses your responses. Hamilton Anxiety Scale (HAM-A) Developed in 1959, the Hamilton test was one of the first rating scales for anxiety. It's still widely used in clinical and research settings. It involves 14 questions that rate moods, fears, and tension, as well as physical, mental, and behavioral traits. A professional must administer the Hamilton test. Beck Anxiety Inventory (BAI) The BAI helps measure the severity of your anxiety. You can take the test by yourself. It may also be given orally by a professional or paraprofessional. There are 21 multiple-choice questions that ask you to rate your experience of symptoms during the past week. These symptoms include tingling, numbness, and fear. Answer options include 'not at all,' 'mildly,' 'moderately,' or 'severely.' Social Phobia Inventory (SPIN) This 17-question self-assessment measures your level of social phobia. You rate your anxiety in relation to various social situations on a scale from zero to four. Zero indicates no anxiety. Four indicates extreme anxiety. Penn State Worry Questionnaire This test is the most widely used measure of worry. It distinguishes between social anxiety disorder and generalized anxiety disorder. The test uses 16 questions to measure your worry's generality, excessiveness, and uncontrollability. Generalized Anxiety Disorder Scale This seven-question test is a screening tool for generalized anxiety disorder. You're asked how often in the past two weeks you've been bothered by feelings of irritability, nervousness, or fear. Options include 'not at all,' 'several days,' 'more than half the days,' or 'nearly every day.' Yale-Brown Obsessive-Compulsive Scale (YBOCS) The YBOCS is used to measure levels of OCD. It's conducted as a one-on-one interview between you and a mental health professional. You choose three items from a symptom checklist that are the most disturbing and then rate how severe they are. Then, you're asked whether you've had certain other obsessions or compulsions in the past. Based on your answers, the mental health professional grades your OCD as subclinical, mild, moderate, severe, or extreme. Mental health disorders that feature anxiety Anxiety is a symptom in several disorders. Some of these include: Disorder Symptoms Panic disorder High amounts of anxiety as well as physical stress for a short amount of time; physical stress can come in the form of dizziness, a high heart rate, sweating, numbness, and other similar symptoms Obsessive-compulsive disorder (OCD) Anxiety expressed as obsessive thoughts or as compulsive behavior that's acted upon repeatedly to relieve stress Phobias Anxiety triggered because of a specific thing or situation that isn't necessarily harmful or dangerous, including animals, heights, or riding in vehicles Social phobias Anxiety that's experienced in interpersonal situations, such as during conversations, in large social groups, or when speaking in front of a crowd The broadest anxiety disorder, generalized anxiety disorder (GAD), is different from these other disorders because it doesn't necessarily relate to a specific cause or behavior. With GAD, you may worry about many different things at once or over time, and the worries are often constant. Diagnostic criteria An anxiety diagnosis depends a lot on your description of the symptoms you're experiencing. Mental health professionals use the 'Diagnostic and Statistical Manual of Mental Disorders' (often called the DSM) to diagnose anxiety and other mental disorders based on symptoms. The criteria differ for each anxiety disorder. The DSM lists the following criteria for generalized anxiety disorder (GAD): excessive anxiety and worry most days about many things for at least six months difficulty controlling your worry appearance of three of the following six symptoms: restlessness, fatigue, irritability, muscle tension, sleep disturbance, and difficulty concentrating symptoms significantly interfering with your life symptoms not being caused by direct psychological effects of medications or medical conditions symptoms aren't due to another mental disorder (e.g. anxiety about oncoming panic attacks with panic disorder, anxiety due to a social disorder, etc.) Anxiety diagnosis in children Childhood and the teenage years are full of new, frightening experiences and events. Some children learn to confront and accept these fears. However, an anxiety disorder can make it difficult or impossible for a child to cope. The same diagnostic criteria and assessments that are used for adults apply to children, too. In the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), your doctor interviews both you and your child about their symptoms. Symptoms in children are similar to those in adults. If you notice anxiety symptoms or any anxious or worrying behaviors that last for more than two weeks, take your child to the doctor. There, they can be checked for an anxiety disorder. Some research suggests that anxiety can have a genetic component. If anyone in your family has ever been diagnosed with anxiety or a depressive disorder, get your child evaluated as soon as you notice symptoms. A proper diagnosis can lead to interventions to help them manage anxiety at a young age. What to do if you're diagnosed with anxiety Focus on managing your anxiety rather than on ending or curing it. Learning how best to control your anxiety can help you live a more fulfilled life. You can work on stopping your anxiety symptoms from getting in the way of reaching your goals or aspirations. To help manage your anxiety, you have several options. Medication If you or your child is diagnosed with anxiety, your doctor will likely refer you to a psychiatrist who can decide what anxiety medications will work best. Sticking to the recommended treatment plan is crucial for the medications to work effectively. Try not to delay your treatment. The earlier you begin, the more effective it will be. Therapy You might also consider seeing a therapist or joining a support group for people with anxiety so that you can talk openly about your anxiety. This can help you control your worries and get to the bottom of what triggers your anxiety. Lifestyle choices Find active ways to relieve your stress. This can lessen the impact that anxiety may have on you. Some things you can do include: Get regular exercise. Find hobbies that engage or occupy your mind. Participate in activities that you enjoy. Keep a daily journal of thoughts and activities. Create short-term or long-term schedules. Socialize with friends. Also, avoid alcohol, nicotine, and other similar drugs. The effects of these substances can make your anxiety worse. Communication Be open with your family and close friends about your diagnosis, if possible. It's not easy to talk about any mental disorder. However, the more the people around you understand your anxiety, the easier it becomes to communicate your thoughts and needs to them. Anxiety relief tips Stick to the treatment plan recommended by your psychiatrist. Consider seeing a therapist or joining a support group for people with anxiety. Find active ways to relieve your stress, such as getting regular exercise or keeping a daily journal. Be open with your family and close friends about your diagnosis, if possible. Avoid alcohol, nicotine, and other similar drugs. Focus on managing your anxiety rather than on ending or curing it.
Medscape
3 hours ago
- Medscape
Fast Five Quiz: Appendicitis
Although the hallmark signs of appendicitis are well known, diagnosis and management evolve. Factors such as the patient's sex, season of presentation, and preceding procedures can influence clinical decision-making and complicate the diagnostic picture. Meanwhile, discussions abound around new treatment options such as nonoperative management with antibiotics and surgical options, including open vs laparoscopic appendectomy. How much do you know about the diagnostic strategies, treatment approaches, and postoperative complications associated with appendicitis? Test your knowledge with this quick quiz. In a patient presenting with signs suggestive of appendicitis after undergoing a colonoscopy, the preferred imaging tool is CT. CT is highly effective at detecting appendiceal inflammation and can help rule out other potential colonoscopy complications (eg, bowel perforation). Although ultrasonography might assist in diagnosing appendicitis, its lower sensitivity and operator dependence limit its reliability, especially in post-colonoscopy cases. Radiography lacks the detail needed to visualize the appendix or diagnose appendicitis reliably, making it unsuitable for this purpose. MRI, although capable of detecting appendicitis, is not typically used in acute-care settings due to its cost, limited availability, and longer acquisition time. Learn more about CT scanning. Surgical approaches tend to differ by sex, with women more commonly receiving minimally invasive procedures (laparoscopic), whereas men more often undergo open surgeries. However, women have a higher chance of developing surgical complications. No significant difference in overall analgesia administration is found between men and women. Although antibiotics are sometimes used to treat appendicitis nonsurgically, limited evidence supports significant sex-based preference for this method, and it is not widely practiced as a standard alternative to surgery. Learn more about laparoscopic appendectomy. Appendicitis tends to occur more frequently during the summer months, as shown in research examining seasonal fluctuations in diagnosis rates. This pattern has been seen in both males and females, with a notable rise in cases during warmer weather, although the exact reason for this increase remains uncertain. Spring and winter do not show as strong a correlation as summer. Fall has not been linked with a noticeable rise in appendicitis cases. Learn more about appendicitis. After an appendectomy, the most frequent issue facing patients is infection at the site of the surgical incision. This complication remains the leading postoperative concern regardless of the surgical technique used. Hernia is not commonly seen after an appendectomy and tends to develop later, often related to improper wound healing or incisional stress. Septicemia and intestinal obstruction are common complications after appendectomy, although they occur less frequently than wound infection. Learn more about hernias. Appendectomy remains the preferred treatment for uncomplicated acute appendicitis, as it consistently offers reliable results and a lower risk for recurrence compared to antibiotics. Although antibiotic therapy can be a safe option for selected patients, especially those aiming to avoid surgery, it carries the potential for treatment failure and future recurrence. Antibiotics are typically the treatment of choice for delayed presentations of appendicitis that are associated with phlegmon formation. Patients who initially receive antibiotics and later need surgery do not appear to have a higher rate of perforation than those who undergo surgery from the outset. Learn more about appendectomies.
Yahoo
a day ago
- Yahoo
EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition NUTLEY, N.J., July 21, 2025 /PRNewswire/ -- Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27 - 31. Eisai will present 21 oral presentations, 24 posters, three (3) symposia and two (2) lecanemab product theaters. Key Oral Lecanemab Presentations Four-year Data: On Wednesday, July 30, as part of the "Developing Topics Session: Innovative Therapeutic Approaches" (8:00 – 8:45 AM EDT), initial four-year findings will be presented on lecanemab from the Phase 3 Clarity AD Open-Label Extension in Early Alzheimer's Disease trial. Subcutaneous Maintenance Dosing: A Featured Research Session on Wednesday, July 30 (9:00 – 10:30 AM EDT) will include data on the potential of a new and convenient option for ongoing lecanemab treatment, the subcutaneous formulation for maintenance dosing. Real World Case Studies: A Developing Topics Session on Sunday, July 27 (9:00 – 10:30 AM EDT) will include data on real-world case studies and patient pathway learnings from diverse U.S. clinical settings two years post-approval of lecanemab. Key Lecanemab Poster Presentation A Poster Presentation on Monday, July 28 (viewing available from 7:30 AM – 4:15 PM EDT) will share findings on cerebrospinal fluid (CSF) samples collected from the Clarity AD trial and analyzed using the novel, sensitive immunoassay developed to measure Aβ protofibrils in CSF. Key Oral E2814 Presentation A Featured Research Session on Wednesday, July 30 (4:15 – 5:45 PM EDT) will include findings from the Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial. "The data presented at AAIC 2025 will highlight long-term findings from lecanemab's open-label extension trial, real-world lecanemab case studies as well as results on a subcutaneous formulation and dosing regimen that may offer patients more flexibility to continue treatment to fight Alzheimer's disease," said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. "We will also share preliminary results from the DIAN-TU-001 NexGen Trial, exploring etalanetug with background lecanemab therapy to slow or prevent the progression of Alzheimer's disease. As we gain more experience using dual-acting lecanemab in different clinical settings and continue to explore new avenues to improve the diagnosis and treatment of Alzheimer's disease, we are hopeful about the future. We remain committed to patients and their loved ones who are impacted by this progressive, relentless disease, caused by a continuous underlying neurotoxic process that begins before and continues after plaque is removed from the brain." Key Featured Research Sessions Featured Research Session (FRS), #1-31-FRS-A: Anti-Amyloid Therapies in Clinical Practice: Real World Evidence and Implementation Consideration 4:15 - 5:45 PM EDT, Sunday, July 27 Session Program Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results (Abstract ID 103048) Featured Research Session, #4-13-FRS-C: Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's Disease 9:00 - 10:30 AM EDT, Wednesday, July 30 Session Program Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations (Abstract ID 104694) Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer's Disease (Abstract ID 104693) Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation (Abstract ID 104691) Subcutaneous Lecanemab: Potential Benefits and Place in Therapy (Abstract ID 104695) Featured Research Session, #4-31-FRS-B: Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial 4:15 - 5:45 PM EDT, Wednesday, July 30 Session Program DIAN-TU-001 Trial (Tau NexGen) Rationale and Enrollment Experience (Abstract ID 105298) Baseline Participant Clinical Characteristics in the DIAN-TU-001 Trial (Abstract ID 105299) Baseline Imaging Characteristics of Participants in the Phase II/III DIAN-TU- 001 Tau NexGen Trial for Dominantly Inherited Alzheimer's Disease (Abstract ID 105301) Lecanemab in DIAD: 6-Month Amyloid PET Results from the DIAN-TU-001 Trial (Abstract ID 105303) Safety of Lecanemab After 6-Month Treatment in the DIAN-TU-001 Trial (Abstract ID 105304) Key Developing Topics Sessions Developing Topics On Real-World Data 8:00 - 8:45 AM EDT on Sunday, July 27 Session Program Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients (Abstract ID 108809) Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway Learnings from Diverse US Clinical Settings 9:00 - 10:30 AM EDT on Sunday, July 27 Session Program Real-World Use of Lecanemab in Patients with Early Alzheimer's Disease in the United States: A Case Series Review (Abstract ID 108599) Real-World Use of Lecanemab with Consideration of Race, Ethnicity and Geographical Diversity (Abstract ID 108602) Real-World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy (Abstract ID 108603) Physician Satisfaction with Lecanemab in Early Alzheimer's Disease: Real- World Insights from Prescribers in the United States (Abstract ID 108605) Real-World Insights on the Lecanemab Patient Pathway in Early Alzheimer's Disease in the United States (Abstract ID 108606) Blood-Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer's Disease in the United States (Abstract ID 108607) Developing Topics On Innovative Therapeutic Approaches 8:00 - 8:45 AM EDT, Wednesday, July 30 Session Program The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer's Disease: Initial Findings from the 48-Month Analysis (Abstract ID 108905) Additional Featured Research and Developing Topics Sessions Biomarkers July 28 (Mon.) 9:00 – 10:30 AM EDT Featured Research Session, #2-17-FRS-A: Sex Specific Risk And Protective Factors in Alzheimer's Disease Sex-Stratified GWAS Meta-Analyses Reveal Novel Sex-Specific Association with CSF Biomarkers of Alzheimer's Disease (Abstract ID 102560) Lecanemab July 29 (Tues.) 2:00 – 3:30 PM EDT Developing Topics Session: Developing Topics On Tau Biomarkers Variations in Plasma p-Tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: The AHEAD 3-45 Study (Abstract ID 108909) Clinical Trials July 30 (Weds.) 2:00 – 3:30 PM EDT Featured Research Session, #4-26-FRS-A: Innovative Use of Statistical Models and Machine Learning to Enhance AD Clinical Trials Baseline Predictions of PACC Progression Trajectories in Preclinical AD Improve the Precision and Power of Treatment Effect Assessments (Abstract ID 99560) Poster Presentations Asset/Project,Presentation Date and Time** Title, Abstract Number Lecanemab July 27 (Sun.) Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector (Abstract ID 106273) Lecanemab July 27 (Sun.) Delphi Consensus for Implementation of Anti-Amyloid mAb Initiation in Private Practice Neurology: Preliminary Recommendations from Experienced Providers (Abstract ID 108789) Lecanemab July 28 (Mon.) Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD (Abstract ID 108918) Lecanemab July 28 (Mon.) Understanding Real-World Clinical Experience with Lecanemab: Capturing the Patient and Care Partner Voice Through Social Media Listening (Abstract ID 102018) Lecanemab July 29 (Tues.) Patient and Care Partner Expectations and Emotional Experiences of Lecanemab: A Social Media Listening Study (Abstract ID 101001) Lecanemab July 29 (Tues.) Lecanemab Real-World Use Perspectives from a New England Alzheimer's Disease Center: A Retrospective Chart Review (Abstract ID 101388) Lecanemab July 30 (Weds.) Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center (Abstract ID 101400) E2025 July 29 (Tues.) Quantification of EphA4 Turnover Rate and Subsequent Validation of Target Engagement for E2025, a Novel Anti-EphA4 Antibody, in Human Neural Cells (Abstract ID 96834) E2814 July 30 (Weds.) E2814 Mitigates Tau Pathology: Inhibiting Tau Uptake and Promoting MTBR- Tau Clearance Through Microglial Pathways in vitro (Abstract ID 102696) Biomarkers and Imaging July 27 (Sun.) External Validation of Joint Propagation Model-Based Tau PET CenTauR Units (Abstract ID 106362) Biomarkers and Imaging July 28 (Mon.) Identifying Differentially Expressed Proteins Between Amyloid Positive and Amyloid Negative Subjects Based on Alamar Multiplex Assay Data Using MissionAD Samples (Abstract ID 107031) Biomarkers and Imaging July 29 (Tues.) Influence of Demographics and Scan Time on MK6240 Off-Target Signal and Reference Region Selection (Abstract ID 100424) Biomarkers July 27 (Sun.) Observational Study Evaluating Blood-Based Biomarker Use for Confirmatory Alzheimer's Disease Diagnosis in Real-World Clinical Practice Within the United States (Abstract ID 99857) Biomarkers July 28 (Mon.) A De Novo-Assisted Strategy to Identify Novel IncRNA-Encoded Peptides in Cerebrospinal Fluid of Demented Subjects With or Without Amyloid Positivity (Abstract ID 106893) Biomarkers July 28 (Mon.) Impact of Blood-Based Biomarkers on Access to Alzheimer's Disease Treatments: A Simulation Study in Japan (Abstract ID 102553) Biomarkers July 29 (Tues.) Implementation Science Study Evaluating the Real-World Use of Blood-Based Biomarkers as Confirmatory Diagnostic Tools for Alzheimer's Disease in the United States (Abstract ID 99804) Biomarkers July 29 (Tues.) Characterization of Lewy Body Copathology in Early AD Clinical Trial Population Demonstrates Similarities and Differences Compared to Natural History Studies in Alzheimer's Disease Patients (Abstract ID 107102) Biomarkers July 30 (Weds.) Value of Blood-Based Biomarker Testing to Diagnose, Identify and Monitor Patients with Alzheimer's Disease: A Structured Literature Review (Abstract ID 99842) Biomarkers July 30 (Weds.) Alzheimer's Disease Molecular Subtypes in a Clinical Trial Cohort (Abstract ID 105257) General AD July 27 (Sun.) Operational Consideration and Best Practices for Implementation of an Early Alzheimer's Disease Patient Care Pathway (Abstract ID 108093) General AD July 27 (Sun.) Estimating Clinical Transitions in Patients with Alzheimer's Using Instrumental Activities of Daily Living (IADL) (Abstract ID 107058) General AD July 28 (Mon.) Staging Alzheimer's Disease Using the Functional Assessment Screening Tool (FAST): A Crosswalk with the Montreal Cognitive Assessment (MoCA) (Abstract ID 107045) General AD July 29 (Tues.) Time to Alzheimer's Disease Diagnosis in Japan: A Retrospective Observational Study (Abstract ID 97026) General AD July 30 (Weds.) Alzheimer's Disease Staging by Instrumental Activities of Daily Living (IADL): A Crosswalk with the Montreal Cognitive Assessment (MoCA) (Abstract ID 107009) **Poster viewing time is set from 7:30 AM – 4:15 PM EDT on the date of presentation Eisai-Sponsored Symposia Asset/Project,Presentation Date and Time Title General AD July 28 (Mon.) 6:00 – 7:30 PM EDT Smoldering Alzheimer's Disease: The Ongoing Benefit of Addressing Multiple Pathologies General AD July 30 (Weds.) 6:15 – 7:45 AM EDT Unlock Your Brain: Exploring Alzheimer's Disease from the Inside Out General AD July 30 (Weds.) 6:00 – 7:30 PM EDT Brain Health Navigator—Ensuring Efficient and Effective Alzheimer's Disease Diagnostic and Clinical Care Pathways Eisai-Sponsored Product Theaters Asset/Project,Presentation Date and Time Title Lecanemab July 27 (Sun.) 12:25 – 1:05 PM EDT Early Diagnosis, Early Treatment: Identifying Patients for Greater Benefit in Mild Cognitive Impairment Due to Alzheimer's Disease Lecanemab July 28 (Mon.) 12:25 – 1:05 PM EDT Best Practices in Early Alzheimer's Disease Care: Creating a Plan from Screening Through Long-Term Treatment Product theaters will feature presentations based on real-world clinical experience with lecanemab - providing attendees with an opportunity to hear best practices and expert guidance on using this therapy. This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. * Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2 MEDIA CONTACTSEisai Inc. (U.S.)Julie Edelman+1-862-213-5915Julie_Edelman@ [Notes to editors] About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved and being marketed in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates,9 the United Kingdom,10 Mexico,11 Macau,12 Oman, Taiwan,13 European Union,14 Qatar, Singapore15 and Thailand16 for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Eisai has submitted applications for approval of lecanemab in 11 countries and July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. References Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi: 10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: July 2025. Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: July 2025. The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: July 2025. Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: July 2025. Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: July 2025. Israel Ministry of Health. The Israeli Drug Registry. Leqembi. Last accessed: July 2025. United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: July 2025. BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: July 2025. COFEPRIS authorizes innovative treatment for Alzheimer's patients. Available at: Last accessed: July 2025. Macau Special Administrative Region Drug Search. Last accessed: July 2025. Taiwan Food and Drug Administration Assessment Report. Last accessed: July 2025. European Medicines Agency. Leqembi | European Medicines Agency (EMA). Last accessed: July 2025. Health Sciences Authority. Last accessed: July 2025. Thailand Food and Drug Administration, Ministry of Public Health. Last accessed: July 2025. View original content to download multimedia: SOURCE Eisai Inc.
